Lirafugratinib (RLY-4008) demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 1/2 ReFocus trial (NCT04526106) presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.1,2
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors